Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06072781 · ClinicalTrials.gov registry record · Phase 3
A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer
A Phase 3 study of Low-Grade Serous Ovarian Cancer, sponsored by Verastem.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 270
- Enrollment target
- 20
- Study locations
NCT06072781: Recruiting Phase 3 study of Low-Grade Serous Ovarian Cancer, sponsored by Verastem.
NCT06072781 is a Phase 3 study of Low-Grade Serous Ovarian Cancer that is actively recruiting participants, run by Verastem. The registered enrollment target is 270 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (65% lower). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06072781, a Phase 3 study of Low-Grade Serous Ovarian Cancer, is actively recruiting participants, sponsored by Verastem.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 270 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will assess the safety and efficacy of avutometinib (VS-6766) in combination with defactinib versus Investigator's choice of treatments (ICT) in subjects with recurrent LGSOC who have progressed on a prior platinum-based therapy.
Primary Outcome
Progression-free survival (PFS) according to RECIST version 1.1, per blinded independent central review (BICR)
Conditions Studied
Interventions
- DRUG Defactinib
- DRUG Paclitaxel
- DRUG Letrozole
- DRUG Pegylated liposomal doxorubicin
- DRUG avutometinib
Study Locations (20)
Florida
- Florida Cancer Specialists - South - Fort Myers
- Mount Sinai - Miami Beach
- AdventHealth - Orlando
- Moffitt Cancer Center - Tampa
- Florida Cancer Specialists Research East - West Palm Beach
California
- UCLA Health - Los Angeles
- UC Davis - Sacramento
- University of California, San Francisco - San Francisco
New York
- Roswell Park Cancer Institute - Buffalo
- Memorial Sloan Kettering Cancer Center - New York
Arizona
- HonorHealth - Phoenix
Arkansas
- University of Arkansas - Little Rock
Connecticut
- Yale University - New Haven
Georgia
- Winship Cancer Institute at Emory University - Atlanta
Illinois
- NorthShore University HealthSystem - Evanston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 270 participants |
| Start Date | 2024-03-18 |
| Est. Completion | 2031-02-09 |
| Phase | Phase 3 |
What NCT06072781 shows while recruiting
NCT06072781 is an interventional study that assigns participants to a tested intervention. The registered 270 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (65% lower).
The record links to 1 condition, with Low-Grade Serous Ovarian Cancer appearing as the primary indexed condition, and to 5 interventions - of which Defactinib is the first listed.
NCT06072781 names 20 study sites across 13 states, led by Florida, California, New York.
Frequently Asked Questions
What is clinical trial NCT06072781 about?
NCT06072781 is a clinical study titled "A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer". This study will assess the safety and efficacy of avutometinib (VS-6766) in combination with defactinib versus Investigator's choice of treatments (ICT) in subjects with recurrent LGSOC who have progressed on a prior platinum-based therapy.
What is the current status of trial NCT06072781?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 270 participants. The study started on 2024-03-18. Estimated completion is 2031-02-09.
What conditions does trial NCT06072781 study?
This clinical trial studies the following conditions: Low-Grade Serous Ovarian Cancer.
What interventions are being tested in trial NCT06072781?
The interventions under investigation include: Defactinib (DRUG), Paclitaxel (DRUG), Letrozole (DRUG), Pegylated liposomal doxorubicin (DRUG), avutometinib (DRUG).
Who is sponsoring clinical trial NCT06072781?
This trial is sponsored by Verastem, which has 21 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06072781 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Low-Grade Serous Ovarian Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06072781's enrollment target sits among peer trials
270 1218th of 2000 higher than 781 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of Avutometinib, Defactinib, and Letrozole in People With Low-Grade Serous Ovarian Cancer
RECRUITING · Phase 2
-
Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00801489 · 270 participants · Phase 2
Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
- NCT04372485 · 270 participants · NA
Using Mobile Health (mHealth) to Improve STI Treatment Adherence Among Adolescents
- NCT04528446 · 270 participants
The Impact of Glomerular Disorders on Bone Quality and Strength
- NCT05215327 · 270 participants · Phase 2
High vs. Standard Dose Influenza Vaccine in Lung Allograft Recipients
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI